KemPharm, Inc. (KMPH)
Stock Price:
$0.480 USD
0.050 (11.63%)
Updated Aug 10, 2020 3:59 PM EDT - End of day
After-hours: $0.479 -0.001 (-0.21%) Aug 10, 4:02 PM
Key Info
| Market Cap |
31.57M |
| Revenue (ttm) |
14.93M |
| Net Income (ttm) |
-17.99M |
| Shares Out |
65.76M |
| EPS (ttm) |
-0.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$0.480 |
| Previous Close |
$0.430 |
| Change ($) |
0.050 |
| Change (%) |
11.63% |
| Day's Open |
0.220 |
| Day's Range |
0.420 - 0.500 |
| Day's Volume |
2,178,881 |
| 52-Week Range |
0.121 - 1.370 |
More Stats
| Market Cap |
31.57M |
| Enterprise Value |
99.77M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
65.76M |
| Float |
56.83M |
| EPS (basic) |
-0.54 |
| EPS (diluted) |
-0.51 |
| FCF / Share |
-0.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
635,833 |
| Short Ratio |
0.41 |
| Short % of Float |
1.14% |
| Beta |
1.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.11 |
| PB Ratio |
n/a |
| Revenue |
14.93M |
| Operating Income |
-12.74M |
| Net Income |
-17.99M |
| Free Cash Flow |
-14.71M |
| Net Cash |
-68.20M |
| Net Cash / Share |
-1.04 |
| Gross Margin |
66.28% |
| Operating Margin |
-85.36% |
| Profit Margin |
-120.50% |
| FCF Margin |
-98.56% |
| ROA |
-51.79% |
| ROE |
n/a |
| ROIC |
-22.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.50
Current: $0.480
High
1.50
Target: 1.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 12.84 | - | - | - | - | - | - |
| Gross Profit | 12.84 | - | - | - | - | - | - |
| Operating Income | -20.34 | -55.90 | -33.37 | -37.48 | -22.81 | -16.44 | -4.72 |
| Net Income | -24.52 | -56.47 | -43.39 | -16.52 | -54.66 | -24.46 | -5.23 |
| Shares Outstanding | 29.65 | 17.93 | 14.65 | 14.60 | 7.37 | 2.38 | 2.38 |
| Earnings Per Share | -0.83 | -3.15 | -2.96 | -1.13 | -7.42 | -10.27 | -2.20 |
| Operating Cash Flow | -23.74 | -54.20 | -33.10 | -29.77 | -20.27 | -14.67 | -4.33 |
| Capital Expenditures | -0.03 | -0.02 | -0.18 | -0.64 | -0.14 | -0.05 | -0.03 |
| Free Cash Flow | -23.76 | -54.22 | -33.28 | -30.42 | -20.40 | -14.72 | -4.36 |
| Cash & Equivalents | 3.56 | 22.38 | 43.33 | 68.87 | 51.32 | 10.26 | 0.00 |
| Total Debt | 79.53 | 82.05 | 93.48 | 91.98 | 21.97 | 18.95 | - |
| Net Cash / Debt | -75.97 | -59.67 | -50.15 | -23.12 | 29.35 | -8.70 | 0.00 |
| Assets | 10.51 | 26.75 | 52.46 | 84.89 | 54.59 | 13.71 | - |
| Liabilities | 84.96 | 93.31 | 110 | 104 | 64.71 | 38.02 | - |
| Book Value | -74.46 | -66.57 | -57.52 | -18.70 | -10.12 | -48.51 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
KemPharm, Inc. |
| Country |
United States |
| Employees |
22 |
| CEO |
Travis C. Mickle |
Stock Information
| Ticker Symbol |
KMPH |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: KMPH |
| IPO Date |
April 16, 2015 |
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.